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Review: use of hormone replacement therapy in
the past 5 years is associated with an increased
risk of breast cancer
Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative
reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast
cancer. Lancet 1997 Oct 11;350:1047–59.
Question
Is hormone replacement therapy (HRT) associated with an
increased risk of breast cancer?
Data sources
Studies were identified from review articles, literature searches,
and colleagues.
Study selection
Studies were selected if they included >100 women with breast
cancer and if information was obtained on the use of HRT and
reproductive and menopausal history.
Data extraction
Data were collected from the investigators for individual women
on their use of HRT and hormonal contraceptives, socio›
demographic factors, family history of breast cancer, height,
weight, age at menarche, reproductive history, gynaecological
surgery, menopausal status, age at menopause, and tumour
spread for those who had breast cancer.
Main results
51 studies from 21 countries involving 52 705 women with inva›
sive breast cancer and 108 411 women without breast cancer
were included (81% of eligible studies). Meta›analyses were
stratified by study, study centre, age at diagnosis, time since
menopause, body mass index, parity, and, when appropriate, age
of the woman at first birth. The main analyses were based on
53 865 postmenopausal women (17 949 with breast cancer and
35 916 without breast cancer) with known age at menopause.
The overall median age at first use of HRT was 48 years. The
relative risk (RR) of breast cancer among women who had used
HRT at some time compared with those who had never used it
was 1.14 (p < 0.001). Compared with women who had never
used HRT, those who had used it for >5 years had an increased
risk (RR 1.35, 95% CI 1.21 to 1.49, p < 0.001); current users
(women who had used HRT at the time of or within 12 months
of the diagnosis of breast cancer) had an increased risk (RR 1.21,
p<0.001); and those who had stopped use >5 years before diag›
nosis had no increase in risk. Among current users or those who
had stopped use 1–4 years previously, the RR increased by a fac›
tor of 1.02 (CI 1.01 to 1.04, p < 0.001) for each year of use. For
women who used HRT < 5 years before diagnosis and the dura›
tion of use was >5 years, an increase in the risk of breast cancer
was associated with age at diagnosis >60 years (RR 1.40), no
family history (RR 1.35), white race (RR 1.25), >13 years of
education (RR 1.49), body mass index < 25.0 kg/m2 (RR 1.52),
>13 years old at menarche (RR 1.42), having had a child (RR
1.34), < 25 years of age at birth of first child (RR 1.41), no use
of oral contraceptives in the past 10 years (RR 1.35), ever hav›
ing smoked (RR 1.56), and natural menopause (RR 1.32). The
RR associated with long durations of current or recent use
decreased with increasing weight (p < 0.001 for trend) and
increasing body mass index (p < 0.001 for trend).
Conclusions
Women who are current or recent users of hormone replace›
ment therapy have an increased risk of breast cancer compared
with those who are never users; this risk is greater with increas›
ing duration of use. Women who stop hormone replacement
therapy have a reduced risk and, after stopping for >5 years,
have no increase in risk.
Source of funding: Imperial Cancer Research Fund.
For article reprint: Professor V Beral, Secretariat, ICRF Cancer Epidemiology Unit, Gibson Building,
Radcliffe Infirmary, Oxford 0X2 6HE, UK. Fax +44 (0)1865 310545.
A modified version of this abstract appears in ACP Journal Club 1998 May–Jun.
Commentary
This timely and long awaited collaborative
work will be of interest to many women.
Both endogenous and exogenous female
hormones have featured in the identifica›
tion of risk factors for breast cancer. Oral
contraceptive use, early menarche, late first
pregnancy, late menopause, and nulliparity
are known to play some part in altering cell
proliferation, differentiation, and atrophy
as the concentrations and duration of hor›
monal excretion vary.1
In contrast, HRT has been widely advo›
cated for perimenopausal and postmeno›
pausal women because it has been shown
to decrease the incidence of cardiovascular
disease, reduce the frequency of oste›
oporotic fractures, and effectively treat
many of the physical and psychological
symptoms associated with menopause. In
this important overview, the authors dealt
with the complexity of the many variant
trials through stratification, resulting in a
detailed study. Because 80% of the women
mostly used preparations containing oes›
trogens alone and only 12% took prepara›
tions containing both oestrogen and pro›
gestagen, there remains too little
information to draw firm conclusions on
the impact of current practice in which
HRTs are used in combination.
Results of this well done meta›analysis
indicate an increased risk of breast cancer
among women who take HRT for >5
years. The risk is related to duration of
treatment and seems to diminish within 5
years of stopping HRT. Counselling about
these risks must also be placed in the con›
text of what is known about the long term
benefits (prevention of coronary events
and fractures), and long term risks (such as
the possibility of endometrial cancer).2 It is
noteworthy that these findings are based
on observational data. We await the results
of the Women’s Health Initiative in the US,
a trial designed specifically to assess the
risks and benefits of long term HRT.
Until results from this trial are available,
we need to openly discuss with women the
potential benefits and risks of HRT in con›
junction with individual concerns and
health priorities.
Marilyn Kirshbaum, RN, RGN, MSc
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